Arrowhead Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
Arrowhead Pharmaceuticals, Inc. (ARWR) filed this Current Report on Form 8-K on May 7, 2026. The filing announces the company's fiscal 2026 financial results for the period ended March 31, 2026. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Select Market.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed financial data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The filing text does not contain specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative analysis.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, contingencies, and unusual items are not detailed in the Form 8-K text itself but are contained within the referenced press release dated May 7, 2026.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific fiscal 2026 revenue and net income figures.
- Verify cash position and liquidity runway details in the full press release.
- Check for any updates to clinical trial timelines or regulatory milestones mentioned in the commentary.
- Confirm if the company provided updated fiscal 2027 guidance in the press release.